BBIO Stock Recent News

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company's Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1).

PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025.

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM

PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025.

Aquinas Wealth Advisors CEO Chris McMahon discusses the state of the economy, the success of healthcare stocks and more on ‘Making Money.' #foxbusiness #fox #usa #us #news #breakingnews #MakingMoney #ChrisMcMahon #WealthExpert #Stocks #StockMarket #Investing #Investment #Finance #Business #Economy #USEconomy #Markets #Alcohol #Liquor #Health #Healthcare #Water #Consumers #Money #WallStreet #BusinessNews

BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Ananth Sridhar - Chief Operating Officer Chinmay Shukla - VP IR & Strategic Finance Christine Siu - Chief Operating Officer in Residence Justin To - Chief Operating Officer, Skeletal Dysplasias and Gene Therapy Matthew Outten - Chief Commercial Officer Neil Kumar - Co-Founder, CEO & Director Thomas Trimarchi - CFO & President Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Biren N. Amin - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Gregory Allen Harrison - Scotiabank Global Banking and Markets, Research Division Lin Tsai - Jefferies LLC, Research Division Mani Foroohar - Leerink Partners LLC, Research Division Paul Choi - Goldman Sachs Group, Inc., Research Division Salim Qader Syed - Mizuho Securities USA LLC, Research Division Tyler Martin Van Buren - TD Cowen, R

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $1.02 per share a year ago.

- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.